Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 29, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 30, 2025
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001423029-25-000009
Filed / recorded
Dec 30, 2025, 10:46 PM UTC
Added to OQRO
Oct 6, 2026, 4:40 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
Issuer CIK
879407
Ticker
ARWR
Reporting person
Christopher Richard Anzalone
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Dec 29, 2025
Transaction code
M
Shares / units
16,545
Price per share
$6.15
Acquired / disposed
Acquired (A)
Shares owned after
3,857,652
Ownership form
Direct
Amendment
No
Footnotes from the filing
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.